Last updated: 2026-09-06 16:46:40. Prices reflect the latest closing data and will resume updating on the next trading day. Stock price data is sourced from Massive.
Allogene Therapeutics, Inc. (ALLO) operates in the BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) sector and is listed on NASDAQ. The stock is currently priced at $1,97, with a market capitalization of $684,07M and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $1,04 to $4,46. This page covers its latest market performance, valuation, price trends and company information.
$684,07M | |
$1,98 | |
$55,00 | |
$0,86 | |
$1,98 | |
4,12M | |
-- | |
-- | |
$4,46 | |
$1,04 | |
-- | |
-- |
Allogene Therapeutics, Inc. (ALLO) last closed at $1,98 as of 2026-09-04 23:53:00, unchanged from the previous close of $1,98.
During the latest regular trading session, ALLO traded between $0,86 and $55,00, with a volume of 4,12M shares. The closing price was near the lower end and near the lower end of its 52-week range.
Over the past seven days, Allogene Therapeutics, Inc. (ALLO) moved from $2,01 to $1,97, representing a decline of 2,24% ($0,04).
The stock traded between $1,96 and $2,01 during the period. The latest price is near the lower end of the 7-day range, indicating moderate downward.
The average daily volume was 4,50 million shares, down versus the previous seven-day period, indicating lower trading activity.
Position in Range: 27,0%
ALLO is currently trading at $1,97, placing it 27,0% of the way from its 52-week low of $1,04 to its 52-week high of $4,46. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
Allogene Therapeutics Inc is a clinical stage immuno-oncology company pioneering the development of genetically engineered allogeneic T cell product candidates for the treatment of cancer and autoimmune diseases. Its pipeline includes "off-the-shelf" T cell candidates designed to target cancer cells or eliminate autoreactive cells in patients with autoimmune disorders. Its three core programs are: Large B-Cell Lymphoma (LBCL), Autoimmune Disease (AID) and Renal Cell Carcinoma (RCC).
| Industry | BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) |
| Employees | 152 |
| Exchange | NASDAQ |
| Company Website |
Eligible investors can buy real shares of Allogene Therapeutics, Inc. (ALLO) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.